Stereotaxis, Inc. (STXS)

CAPS Rating:

The Company designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite, or cath lab.

View All Commentary (STXS)

Recs

1

Avatar jimandjo4 (< 20) Submitted: 8/23/06 3:22 PM : Start Price: $11.16 STXS Score: -41.62

They sell a device which has no real competition.
Problem is, the medical device is very expensive.
They seem to have turned things around, and are making progress. This stock is not for the faint hearted, but could have a one hundred percent increase by mid or late 2007.

Report this Post Replies: 2 | Reply

Avatar Lfierz (60.73) Submitted: 10/02/06 8:02 PM

Recs: 1 | Rec This

The device can do things no other method can in interventional cardiology and neuroradiology. It shortens intervention time. It reduces x-ray exposition, definitely for the patient, even to zero for the examining doctors. Doctors do not need to wear a heavy plumb coats for most of the day. Less backache for them.

STXS is firmly implanted in the top and premium institutions in the USA and overseas. Heavyweight Siemens is helping with development of new applications and sales. Hospitals wanting to attract and retain top doctors and discerning patients will soon have to buy the device. The story will unfold similar to ISRG, just three years later. Just my opinion.

Lukas Fierz, M.D. Switzerland

Report this Post Reply

Avatar FutureMonkey (73.40) Submitted: 1/13/07 10:33 AM

Recs: 0 | Rec This

"No real competition" is not an entirely accurate statement. Today they have no competition, tomorrow the field may get crowded. Being the first mover is a decided advantage, but another product that is easier, less expensive, or demonstrably better could easily swipe substantial market share from Sterotaxis (or since minimal market penetration to date - replace Sterotaxis as the first mover). Hansen's Sensei product is less expensive, does not require remodeling the catheter lab, and can be moved from cath lab to cath lab around the hospital. Not the perfect stock either, but could be a stiff challenger to STXS for the navigable catheter market.

Report this Post Reply

Stereotaxis, Inc. (STXS)

1

Featured Broker Partners